NCT05918198招募中2 期
Clinical Study of BCL-2 Inhibitor Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 52
- 试验地点
- 1
- 主要终点
- CR/CRi rate
研究概览
简要总结
The goal of this clinical trial is to test the safety and efficacy of venetoclax plus CAG regimen in refractory/relapsed acute myeloid leukemia patients.
详细描述
The main questions it aims to answer are:
- Safety of Ven combined with CAG regimen in the treatment of relapsed/refractory AML patients
- Efficacy of Ven combined with CAG regimen in the treatment of relapsed/refractory AML patients Participants will receive therapy of venetoclax and CAG regimen (Ara-C, Acla and C C-GSF)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years ≤ age ≤ 75 years, male and female are not limited.
- •According to bone marrow morphology and immunophenotype, it was diagnosed as acute myeloid leukemia ( WHO 2016 diagnostic criteria).
- •Morphological recurrence after complete remission (CR) (leukemic cells in the peripheral blood of CR patients or more than 5% of the blasts in the bone marrow or new pathological hematopoiesis or extramedullary leukemic cell infiltration) or acute myeloid leukemia patients who did not achieved CR after 1 cycle of chemotherapy.
- •The ECOG (Eastern Cancer Cooperation Group of the United States) PS score is 0-
- •The expected survival time is ≥ 12 weeks.
- •Female patients of childbearing age need to undergo pregnancy examination before receiving chemotherapy, and must agree to take effective contraceptive measures during treatment.
- •Subjects volunteered to participate, fully informed consent, signed an informed consent, and good compliance.
排除标准
- •Other malignant hematological diseases that do not conform to the diagnosis of acute myeloid leukemia.
- •Allergy to any drugs involved in the project.
- •History of serious cardiovascular and cerebrovascular diseases: ① Congestive heart failure, unstable angina pectoris, myocardial infarction, stroke or poorly controlled arrhythmia with NYHA grade II or above occurred within 12 months before enrollment，LVEF (left ventricular ejection fraction)<50% by color Doppler ultrasound，Corrected QT interval (QTc)>480ms (calculated by Fridericia method, if the QTc is abnormal, it can be detected continuously for 3 times every 2 minutes, and the average value is taken)，Hypertension difficult to control by drugs (systolic blood pressure (BP) ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg) (based on the average of ≥ 3 BP readings obtained from ≥ 2 measurements)，Have had hypertensive crisis or hypertensive encephalopathy in the past.
- •There are other obvious bleeding tendencies or evidence of major coagulation disorders: ①Hemoptysis of any reason occurred within 2 weeks before enrollment，② Thrombosis or embolism occurred within 6 months before enrollment，③ Anticoagulant therapy for therapeutic purposes (except low molecular weight heparin therapy) be used within 2 weeks before enrollment④ Antiplatelet therapy is required.
- •Abnormal liver function: total bilirubin>3 mg/dL；Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 5 × Upper limit of normal value (ULN).
- •Abnormal renal function: serum creatinine ≥ 1.5 × ULN, or the creatinine clearance rate (CrCl) calculated according to Cockroft-Gault formula is less than 60 mL/min (if the calculated CrCl is less than 60 mL/min, the researcher may ask to confirm the 24-hour CrCl, in this case, the subjects with 24-hour CrCl less than 60 mL/min should be excluded).
- •Other serious diseases that may limit the patient's participation in this clinical trial (including but not limited to other malignant tumors, active infection, serious uncured wounds, active ulcers and untreated fractures, history of human immunodeficiency virus infection, and receiving allogeneic stem cells or solid organ transplantation).
- •Cannot swallow pills, malabsorption syndrome or any condition that affects gastrointestinal absorption.
- •Other clinical trials are being conducted.
- •Unable to understand or cooperate to complete the research protocol.
- •Pregnant and lactating patients
- •Other situations that the researcher believes are not suitable for inclusion in the study.
研究组 & 干预措施
Ven+CAG
Experimental
Venetoclax plus CAG regimen
干预措施: Ven+CAG (Drug)
结局指标
主要结局
CR/CRi rate
时间窗: 2 to 3 weeks after the end of cycle 2 (each cycle is 14 days)
the rate of complete remission or complete remission with incomplete hematologic recovery
次要结局
- objective remission rate（ORR）(2 to 3 weeks after the end of cycle 2 (each cycle is 14 days))
- MRD status(2 to 3 weeks after the end of cycle 2 (each cycle is 14 days))
- The incidence of adverse events(Throughout the whole research process, assessed up to 24 months)
- Progression-free survival (PFS)(Throughout the whole research process, assessed up to 24 months)
- Overall survival(Throughout the whole research process, assessed up to 24 months)
研究者
Wen-Jing Yu, MD
Peking University People's Hospital
Peking University People's Hospital
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple MyelomaMultiple MyelomaNCT06042725Mayo Clinic16
招募中
1 期
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaNCT03214562M.D. Anderson Cancer Center116
已完成
1 期
Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Blastic Plasmacytoid Dendritic Cell NeoplasmNCT03485547Dana-Farber Cancer Institute5
招募中
2 期
Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAMLSecondary Acute Myeloid LeukemiaNCT05513131The First Affiliated Hospital with Nanjing Medical University30
招募中
1 期
Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ARTHIV-1-infectionNCT05668026University of Aarhus18